Wednesday July 14, 4:11 pm ,,VISX Reports Record Revenues and Earnings SANTA CLARA, Calif.--(BW HealthWire)--July 14, 1999--VISX, INCORPORATED (Nasdaq NM: VISX - news) today announced financial results for the second quarter ended June 30, 1999.
Revenue for the second quarter of 1999 was $62,503,000 compared to $31,663,000 for the comparable period of the prior year. Net income was $21,526,000, or $0.32 per share, in the second quarter of 1999 compared to a net loss of ($15,329,000), or ($0.25) per share, in the comparable period of the prior year which included a $35,000,000 litigation settlement.
Revenue for the six-month period ended June 30, 1999 was $116,452,000 compared to $55,973,000 for the comparable period of the prior year. Net income was $41,257,000, or $0.61 per share, for the six-month period ended June 30, 1999 compared to a net loss of ($6,367,000), or ($0.10) per share, in the comparable period of the prior year which included a $35,000,000 litigation settlement.
Commenting on the announcement, Mark B. Logan, Chairman and Chief Executive Officer of VISX, stated, ''Another tremendous quarter with record results.'' Mr. Logan went on to say, ''We are closing in on the one millionth procedure performed in the U.S. on VISX lasers since FDA approval. The driving force in this market is the outstanding results experienced by consumers who have had their vision corrected on VISX systems by VISX-trained physicians. The recent start of our consumer advertising campaign is intended to strengthen our leadership in the dynamic laser vision correction industry.''
The foregoing statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and actual results could differ materially. Factors that could affect the Company's business include: fluctuations in customer orders for systems and VisionKey® cards, acceptance of the laser vision correction procedure in the market, competition from other laser systems (a number of which have now received FDA pre-market approval for United States commercial sale), competition from other vision correction products and procedures that are currently in use or that may be developed and introduced in the future, the degree to which VISX is successful in generating royalty income from its patent rights or in enforcing its patent rights, and developments in pending or future patent and antitrust litigation. Additional discussion of factors affecting the Company's business is contained in the Company's most recent filings with the Securities and Exchange Commission, including VISX's Annual Report and Form 10-K for the year ended December 31, 1998 and VISX's Form 10-Q for the quarter ended March 31, 1999.
VISX is a worldwide leader in the development of refractive laser technology. VISX systems are commercially available in the United States and markets worldwide.
VISX, Incorporated Condensed Consolidated Statement of Operations (In thousands, except per share amounts)
(Unaudited) Three Months Ended Six Months Ended 6/30/99 6/30/98 6/30/99 6/30/98
System sales $ 14,848 $ 9,435 $ 26,762 $ 16,995 License, service and other revenue 47,655 22,228 89,690 38,978 Total revenue 62,503 31,663 116,452 55,973
Cost of revenues 12,496 7,477 23,093 13,307 Marketing, general and administrative 12,968 6,956 22,061 12,654 Research, development and regulatory 3,316 2,806 6,951 5,217 Total costs and expenses 28,780 17,239 52,105 31,178 Income from operations 33,723 14,424 64,347 24,795
Interest and other income, net 2,532 1,380 4,414 2,801 Litigation settlement -- (35,000) -- (35,000) Income before provision for income taxes 36,255 (19,196) 68,761 (7,404) Provision for income taxes 14,729 (3,867) 27,504 (1,037) Net income $ 21,526 $ (15,329) $ 41,257 $ (6,367)
Earnings Per Share Basic $ 0.34 $ (0.25) $ 0.66 $ (0.10) Diluted $ 0.32 $ (0.25) $ 0.61 $ (0.10)
Shares Used For Earnings Per Share Basic 63,283 60,760 62,711 60,813 Diluted 68,185 60,760 67,522 60,813
Condensed Consolidated Balance Sheet (in thousands)
(Unaudited) 6/30/99 12/31/98
Cash, cash equivalents and short-term investments $ 189,362 $ 116,539 Accounts receivable 36,426 27,822 Inventories 9,076 6,820 Other current assets 20,895 15,457 Current assets 255,759 166,638 Property and equipment, net 5,150 4,318 Other assets 6,380 5,663 Total assets $ 267,289 $ 176,619
Accounts payable $ 6,909 $ 3,682 Accrued liabilities 39,635 33,948 Current liabilities 46,544 37,630 Stockholders' equity 220,745 138,989 Total liabilities and stockholders' equity $ 267,289 $ 176,619
|